Published in Pharmacogenomics on December 21, 2011
Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin. Semin Thromb Hemost (2012) 0.81
Association of GGCX gene polymorphism with warfarin dose in atrial fibrillation population in Xinjiang. Lipids Health Dis (2013) 0.78
A review of a priori regression models for warfarin maintenance dose prediction. PLoS One (2014) 0.75
PharmGKB summary: very important pharmacogene information for CYP4F2. Pharmacogenet Genomics (2015) 0.75
Global variation in copy number in the human genome. Nature (2006) 57.50
Detection of large-scale variation in the human genome. Nat Genet (2004) 49.18
Mapping and sequencing of structural variation from eight human genomes. Nature (2008) 30.28
Origins and functional impact of copy number variation in the human genome. Nature (2009) 23.63
A high-resolution survey of deletion polymorphism in the human genome. Nat Genet (2005) 16.99
Segmental duplications and copy-number variation in the human genome. Am J Hum Genet (2005) 13.33
Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med (2009) 12.63
Mapping copy number variation by population-scale genome sequencing. Nature (2011) 12.55
An initial map of insertion and deletion (INDEL) variation in the human genome. Genome Res (2006) 11.60
Diversity of human copy number variation and multicopy genes. Science (2010) 8.97
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med (2005) 8.77
Structural variation in the human genome and its role in disease. Annu Rev Med (2010) 7.85
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet (1999) 7.39
Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA (2002) 5.26
The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood (2005) 4.91
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther (2008) 4.54
A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet (2009) 4.32
CYP4F2 genetic variant alters required warfarin dose. Blood (2008) 4.23
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood (2008) 4.02
Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J (2005) 3.75
Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest (2001) 3.64
Oral anticoagulant drugs. N Engl J Med (1991) 3.64
Natural genetic variation caused by small insertions and deletions in the human genome. Genome Res (2011) 3.00
Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood (2010) 2.93
Genome-wide copy-number-variation study identified a susceptibility gene, UGT2B17, for osteoporosis. Am J Hum Genet (2008) 2.65
Warfarin pharmacogenetics. Pharmacotherapy (2008) 2.50
Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J (2006) 2.40
Experience with carrier screening and prenatal diagnosis for 16 Ashkenazi Jewish genetic diseases. Hum Mutat (2010) 2.29
Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther (2010) 2.21
Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clin Pharmacol Ther (2009) 2.04
The clinical context of copy number variation in the human genome. Expert Rev Mol Med (2010) 2.00
Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Am J Hum Genet (2008) 1.99
Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin Pharmacol Ther (2010) 1.88
Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics (2010) 1.82
Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet (1991) 1.60
A genome-wide comparison of the functional properties of rare and common genetic variants in humans. Am J Hum Genet (2011) 1.56
Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. Pharmacogenomics (2008) 1.50
Genetic warfarin dosing: tables versus algorithms. J Am Coll Cardiol (2011) 1.43
The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans. Clin Pharmacol Ther (2011) 1.43
Gamma-glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose. J Thromb Haemost (2007) 1.41
CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing. Pharmacogenomics (2009) 1.37
Human SULT1A1 gene: copy number differences and functional implications. Hum Mol Genet (2006) 1.37
A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clin Pharmacol Ther (2010) 1.35
Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese. Hum Mol Genet (2010) 1.30
Pharmacogenetics of warfarin: development of a dosing algorithm for brazilian patients. Clin Pharmacol Ther (2008) 1.27
Autism genetics: emerging data from genome-wide copy-number and single nucleotide polymorphism scans. Expert Rev Mol Diagn (2009) 1.22
Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients. Pharmacogenet Genomics (2011) 1.20
Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics. Pharmacogenomics (2008) 1.14
Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9. Pharmacogenet Genomics (2010) 1.14
Copy number variants and pharmacogenomics. Pharmacogenomics (2006) 1.13
Pharmacogenetic screening of the gene deletion and duplications of CYP2D6. Drug Metab Rev (2007) 1.10
Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing. J Mol Diagn (2010) 1.06
Gamma-glutamyl carboxylase and its influence on warfarin dose. Thromb Haemost (2010) 1.02
Population-specific GSTM1 copy number variation. Hum Mol Genet (2008) 0.96
Copy number variants in pharmacogenetic genes. Trends Mol Med (2011) 0.96
Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population. J Thromb Haemost (2010) 0.96
Warfarin pharmacogenomics. Curr Opin Mol Ther (2009) 0.94
Copy-number variation genotyping of GSTT1 and GSTM1 gene deletions by real-time PCR. Clin Chem (2009) 0.94
Comparison of warfarin pharmacogenetic dosing algorithms in a racially diverse large cohort. Pharmacogenomics (2011) 0.94
Sulfotransferase gene copy number variation: pharmacogenetics and function. Cytogenet Genome Res (2009) 0.89
Novel association strategy with copy number variation for identifying new risk Loci of human diseases. PLoS One (2010) 0.88
10 years of oral anticoagulant pharmacogenomics: what difference will it make? A critical appraisal. Pharmacogenomics (2009) 0.86
High-resolution SNP and haplotype maps of the human gamma-glutamyl carboxylase gene (GGCX) and association study between polymorphisms in GGCX and the warfarin maintenance dose requirement of the Japanese population. J Hum Genet (2007) 0.86
CNVs of human genes and their implication in pharmacogenetics. Cytogenet Genome Res (2009) 0.80
Pharmacogenetics: technologies to detect copy number variations. Curr Opin Mol Ther (2009) 0.79
EPHX1 polymorphisms are not associated with warfarin response in an Italian population. Clin Pharmacol Ther (2011) 0.79
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 10.24
Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med (2011) 8.93
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2012) 7.94
Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2013) 7.70
2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2010) 7.54
A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med (2013) 7.09
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2012) 6.94
2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation (2013) 5.02
In vivo visualization of embryonic stem cell survival, proliferation, and migration after cardiac delivery. Circulation (2006) 4.48
Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 4.01
Common variants in KCNN3 are associated with lone atrial fibrillation. Nat Genet (2010) 3.97
Variants in ZFHX3 are associated with atrial fibrillation in individuals of European ancestry. Nat Genet (2009) 3.80
High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet (2006) 3.78
Genome-wide association study of PR interval. Nat Genet (2010) 3.73
Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet (2012) 3.71
2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2008) 3.70
2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 3.63
2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg (2014) 3.59
Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA (2005) 3.54
Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med (2006) 3.38
Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. Genet Med (2004) 3.32
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet (2013) 3.21
Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 3.11
Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med (2005) 2.95
Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype. Kidney Int (2003) 2.94
Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol (2012) 2.77
Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol (2007) 2.73
2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2011) 2.71
Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet (2004) 2.60
American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation (2003) 2.52
Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium. J Am Heart Assoc (2013) 2.47
2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol (2008) 2.46
2011 ACCF/AHA guideline for coronary artery bypass graft surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg (2012) 2.40
Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest (2008) 2.39
P wave duration and risk of longitudinal atrial fibrillation in persons ≥ 60 years old (from the Framingham Heart Study). Am J Cardiol (2011) 2.39
Atrial fibrillation: current knowledge and future directions in epidemiology and genomics. Circulation (2011) 2.36
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J (2011) 2.31
Experience with carrier screening and prenatal diagnosis for 16 Ashkenazi Jewish genetic diseases. Hum Mutat (2010) 2.29
Differentiation, survival, and function of embryonic stem cell derived endothelial cells for ischemic heart disease. Circulation (2007) 2.21
Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant (2009) 2.17
Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int (2002) 2.15
Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Am J Hum Genet (2008) 1.99
European ancestry as a risk factor for atrial fibrillation in African Americans. Circulation (2010) 1.90
Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation (2007) 1.87